Asthma and COPD Drugs Market
Asthma and COPD Drugs Market - Global Industry Assessment & Forecast
Segments Covered
- By Diseases Asthma, COPD
- By Medication Class Combination Drugs, Bronchodilators, Inhaled Corticosteroids (ICS), Short Acting Beta Agonists (SABA), Long Acting Beta Agonists (LABA), Leukotriene Antagonists (LTA), Anticholinergics, Anti-Inflammatories, Other Classes
- By Distribution Channel Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Drug Stores
- By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
Base Year: | 2023 |
Forecast Years: | 2024 - 2032 |
Historical Years: | 2018 - 2022 |
Revenue 2023: | USD 37.42 Billion |
Revenue 2032: | USD 57.56 Billion |
Revenue CAGR (2024 - 2032): | 4.9% |
Fastest Growing Region (2024 - 2032) | Europe |
Largest Region (2023): | North America |
Customization Offered
- Cross-segment Market Size and Analysis for Mentioned Segments
- Additional Company Profiles (Upto 5 With No Cost)
- Additional Countries (Apart From Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request Customization Speak To Analyst
-
Executive Dashboard
- Strategic Imperatives
-
Premium Insights
- Top 3 Trends to Watch
- Demand and Supply Trends
- Top 3 Strategies Followed by Major Players
- Top 3 Predictions by Vantage Market Research
- Top Investment Pockets
- Insights from Primary Respondents
-
Global Asthma and COPD Drugs Market - Segment Analysis
- Overview
- Global Asthma and COPD Drugs Market, 2016 - 2028 (USD Million)
-
Global Asthma and COPD Drugs Market - by Diseases
- By Asthma
- By COPD
-
Global Asthma and COPD Drugs Market - by Medication Class
- By Combination Drugs
- By Bronchodilators
- By Inhaled Corticosteroids (ICS)
- By Short Acting Beta Agonists (SABA)
- By Long Acting Beta Agonists (LABA)
- By Leukotriene Antagonists (LTA)
- By Anticholinergics
- By Anti-Inflammatories
- By Other Classes
-
Global Asthma and COPD Drugs Market - by Distribution Channel
- By Retail Pharmacies
- By Hospital Pharmacies
- By Online Pharmacies
- By Drug Stores
-
Global Asthma and COPD Drugs Market - by region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
- Market comparative analysis
-
North America Asthma and COPD Drugs Market - Segment Analysis
- Overview
- North America Asthma and COPD Drugs Market, 2016 - 2028 (USD Million)
-
North America Asthma and COPD Drugs Market, by Diseases
- By Asthma
- By COPD
-
North America Asthma and COPD Drugs Market, by Medication Class
- By Combination Drugs
- By Bronchodilators
- By Inhaled Corticosteroids (ICS)
- By Short Acting Beta Agonists (SABA)
- By Long Acting Beta Agonists (LABA)
- By Leukotriene Antagonists (LTA)
- By Anticholinergics
- By Anti-Inflammatories
- By Other Classes
-
North America Asthma and COPD Drugs Market, by Distribution Channel
- By Retail Pharmacies
- By Hospital Pharmacies
- By Online Pharmacies
- By Drug Stores
-
North America Asthma and COPD Drugs Market, by Country
- U.S.
- U.S. Asthma and COPD Drugs Market, By Diseases
- By Asthma
- By COPD
- U.S. Asthma and COPD Drugs Market, By Medication Class
- By Combination Drugs
- By Bronchodilators
- By Inhaled Corticosteroids (ICS)
- By Short Acting Beta Agonists (SABA)
- By Long Acting Beta Agonists (LABA)
- By Leukotriene Antagonists (LTA)
- By Anticholinergics
- By Anti-Inflammatories
- By Other Classes
- U.S. Asthma and COPD Drugs Market, By Distribution Channel
- By Retail Pharmacies
- By Hospital Pharmacies
- By Online Pharmacies
- By Drug Stores
- U.S. Asthma and COPD Drugs Market, By Diseases
- Canada
- Canada Asthma and COPD Drugs Market, By Diseases
- By Asthma
- By COPD
- Canada Asthma and COPD Drugs Market, By Medication Class
- By Combination Drugs
- By Bronchodilators
- By Inhaled Corticosteroids (ICS)
- By Short Acting Beta Agonists (SABA)
- By Long Acting Beta Agonists (LABA)
- By Leukotriene Antagonists (LTA)
- By Anticholinergics
- By Anti-Inflammatories
- By Other Classes
- Canada Asthma and COPD Drugs Market, By Distribution Channel
- By Retail Pharmacies
- By Hospital Pharmacies
- By Online Pharmacies
- By Drug Stores
- Canada Asthma and COPD Drugs Market, By Diseases
- Mexico
- Mexico Asthma and COPD Drugs Market, By Diseases
- By Asthma
- By COPD
- Mexico Asthma and COPD Drugs Market, By Medication Class
- By Combination Drugs
- By Bronchodilators
- By Inhaled Corticosteroids (ICS)
- By Short Acting Beta Agonists (SABA)
- By Long Acting Beta Agonists (LABA)
- By Leukotriene Antagonists (LTA)
- By Anticholinergics
- By Anti-Inflammatories
- By Other Classes
- Mexico Asthma and COPD Drugs Market, By Distribution Channel
- By Retail Pharmacies
- By Hospital Pharmacies
- By Online Pharmacies
- By Drug Stores
- Mexico Asthma and COPD Drugs Market, By Diseases
- U.S.
-
Europe Asthma and COPD Drugs Market - Segment Analysis
- Overview
- Europe Asthma and COPD Drugs Market, 2016 - 2028 (USD Million)
-
Europe Asthma and COPD Drugs Market, by Diseases
- By Asthma
- By COPD
-
Europe Asthma and COPD Drugs Market, by Medication Class
- By Combination Drugs
- By Bronchodilators
- By Inhaled Corticosteroids (ICS)
- By Short Acting Beta Agonists (SABA)
- By Long Acting Beta Agonists (LABA)
- By Leukotriene Antagonists (LTA)
- By Anticholinergics
- By Anti-Inflammatories
- By Other Classes
-
Europe Asthma and COPD Drugs Market, by Distribution Channel
- By Retail Pharmacies
- By Hospital Pharmacies
- By Online Pharmacies
- By Drug Stores
-
Europe Asthma and COPD Drugs Market, by Country
- Germany
- Germany Asthma and COPD Drugs Market, By Diseases
- By Asthma
- By COPD
- Germany Asthma and COPD Drugs Market, By Medication Class
- By Combination Drugs
- By Bronchodilators
- By Inhaled Corticosteroids (ICS)
- By Short Acting Beta Agonists (SABA)
- By Long Acting Beta Agonists (LABA)
- By Leukotriene Antagonists (LTA)
- By Anticholinergics
- By Anti-Inflammatories
- By Other Classes
- Germany Asthma and COPD Drugs Market, By Distribution Channel
- By Retail Pharmacies
- By Hospital Pharmacies
- By Online Pharmacies
- By Drug Stores
- Germany Asthma and COPD Drugs Market, By Diseases
- UK
- UK Market, By Diseases
- By Asthma
- By COPD
- UK Market, By Medication Class
- By Combination Drugs
- By Bronchodilators
- By Inhaled Corticosteroids (ICS)
- By Short Acting Beta Agonists (SABA)
- By Long Acting Beta Agonists (LABA)
- By Leukotriene Antagonists (LTA)
- By Anticholinergics
- By Anti-Inflammatories
- By Other Classes
- UK Market, By Distribution Channel
- By Retail Pharmacies
- By Hospital Pharmacies
- By Online Pharmacies
- By Drug Stores
- UK Market, By Diseases
- France
- France Asthma and COPD Drugs Market, By Diseases
- By Asthma
- By COPD
- France Asthma and COPD Drugs Market, By Medication Class
- By Combination Drugs
- By Bronchodilators
- By Inhaled Corticosteroids (ICS)
- By Short Acting Beta Agonists (SABA)
- By Long Acting Beta Agonists (LABA)
- By Leukotriene Antagonists (LTA)
- By Anticholinergics
- By Anti-Inflammatories
- By Other Classes
- France Asthma and COPD Drugs Market, By Distribution Channel
- By Retail Pharmacies
- By Hospital Pharmacies
- By Online Pharmacies
- By Drug Stores
- France Asthma and COPD Drugs Market, By Diseases
- Spain
- Spain Asthma and COPD Drugs Market, By Diseases
- By Asthma
- By COPD
- Spain Asthma and COPD Drugs Market, By Medication Class
- By Combination Drugs
- By Bronchodilators
- By Inhaled Corticosteroids (ICS)
- By Short Acting Beta Agonists (SABA)
- By Long Acting Beta Agonists (LABA)
- By Leukotriene Antagonists (LTA)
- By Anticholinergics
- By Anti-Inflammatories
- By Other Classes
- Spain Asthma and COPD Drugs Market, By Distribution Channel
- By Retail Pharmacies
- By Hospital Pharmacies
- By Online Pharmacies
- By Drug Stores
- Spain Asthma and COPD Drugs Market, By Diseases
- Italy
- Italy Asthma and COPD Drugs Market, By Diseases
- By Asthma
- By COPD
- Italy Asthma and COPD Drugs Market, By Medication Class
- By Combination Drugs
- By Bronchodilators
- By Inhaled Corticosteroids (ICS)
- By Short Acting Beta Agonists (SABA)
- By Long Acting Beta Agonists (LABA)
- By Leukotriene Antagonists (LTA)
- By Anticholinergics
- By Anti-Inflammatories
- By Other Classes
- Italy Asthma and COPD Drugs Market, By Distribution Channel
- By Retail Pharmacies
- By Hospital Pharmacies
- By Online Pharmacies
- By Drug Stores
- Italy Asthma and COPD Drugs Market, By Diseases
- BENELUX
- BENELUX Asthma and COPD Drugs Market, By Diseases
- By Asthma
- By COPD
- BENELUX Asthma and COPD Drugs Market, By Medication Class
- By Combination Drugs
- By Bronchodilators
- By Inhaled Corticosteroids (ICS)
- By Short Acting Beta Agonists (SABA)
- By Long Acting Beta Agonists (LABA)
- By Leukotriene Antagonists (LTA)
- By Anticholinergics
- By Anti-Inflammatories
- By Other Classes
- BENELUX Asthma and COPD Drugs Market, By Distribution Channel
- By Retail Pharmacies
- By Hospital Pharmacies
- By Online Pharmacies
- By Drug Stores
- BENELUX Asthma and COPD Drugs Market, By Diseases
- Rest of Europe
- Rest Of Europe Asthma and COPD Drugs Market, By Diseases
- By Asthma
- By COPD
- Rest Of Europe Asthma and COPD Drugs Market, By Medication Class
- By Combination Drugs
- By Bronchodilators
- By Inhaled Corticosteroids (ICS)
- By Short Acting Beta Agonists (SABA)
- By Long Acting Beta Agonists (LABA)
- By Leukotriene Antagonists (LTA)
- By Anticholinergics
- By Anti-Inflammatories
- By Other Classes
- Rest Of Europe Asthma and COPD Drugs Market, By Distribution Channel
- By Retail Pharmacies
- By Hospital Pharmacies
- By Online Pharmacies
- By Drug Stores
- Rest Of Europe Asthma and COPD Drugs Market, By Diseases
- Germany
-
Asia Pacific Asthma and COPD Drugs Market - Segment Analysis
- Overview
- Asia Pacific Asthma and COPD Drugs Market, 2016 - 2028 (USD Million)
-
Asia Pacific Asthma and COPD Drugs Market, by Diseases
- By Asthma
- By COPD
-
Asia Pacific Asthma and COPD Drugs Market, by Medication Class
- By Combination Drugs
- By Bronchodilators
- By Inhaled Corticosteroids (ICS)
- By Short Acting Beta Agonists (SABA)
- By Long Acting Beta Agonists (LABA)
- By Leukotriene Antagonists (LTA)
- By Anticholinergics
- By Anti-Inflammatories
- By Other Classes
-
Asia Pacific Asthma and COPD Drugs Market, by Distribution Channel
- By Retail Pharmacies
- By Hospital Pharmacies
- By Online Pharmacies
- By Drug Stores
-
Asia Pacific Asthma and COPD Drugs Market, by Country
- China
- China Asthma and COPD Drugs Market, By Diseases
- By Asthma
- By COPD
- China Asthma and COPD Drugs Market, By Medication Class
- By Combination Drugs
- By Bronchodilators
- By Inhaled Corticosteroids (ICS)
- By Short Acting Beta Agonists (SABA)
- By Long Acting Beta Agonists (LABA)
- By Leukotriene Antagonists (LTA)
- By Anticholinergics
- By Anti-Inflammatories
- By Other Classes
- China Asthma and COPD Drugs Market, By Distribution Channel
- By Retail Pharmacies
- By Hospital Pharmacies
- By Online Pharmacies
- By Drug Stores
- China Asthma and COPD Drugs Market, By Diseases
- Japan
- Japan Asthma and COPD Drugs Market, By Diseases
- By Asthma
- By COPD
- Japan Asthma and COPD Drugs Market, By Medication Class
- By Combination Drugs
- By Bronchodilators
- By Inhaled Corticosteroids (ICS)
- By Short Acting Beta Agonists (SABA)
- By Long Acting Beta Agonists (LABA)
- By Leukotriene Antagonists (LTA)
- By Anticholinergics
- By Anti-Inflammatories
- By Other Classes
- Japan Asthma and COPD Drugs Market, By Distribution Channel
- By Retail Pharmacies
- By Hospital Pharmacies
- By Online Pharmacies
- By Drug Stores
- Japan Asthma and COPD Drugs Market, By Diseases
- India
- India Asthma and COPD Drugs Market, By Diseases
- By Asthma
- By COPD
- India Asthma and COPD Drugs Market, By Medication Class
- By Combination Drugs
- By Bronchodilators
- By Inhaled Corticosteroids (ICS)
- By Short Acting Beta Agonists (SABA)
- By Long Acting Beta Agonists (LABA)
- By Leukotriene Antagonists (LTA)
- By Anticholinergics
- By Anti-Inflammatories
- By Other Classes
- India Asthma and COPD Drugs Market, By Distribution Channel
- By Retail Pharmacies
- By Hospital Pharmacies
- By Online Pharmacies
- By Drug Stores
- India Asthma and COPD Drugs Market, By Diseases
- South Korea
- South Korea Asthma and COPD Drugs Market, By Diseases
- By Asthma
- By COPD
- South Korea Asthma and COPD Drugs Market, By Medication Class
- By Combination Drugs
- By Bronchodilators
- By Inhaled Corticosteroids (ICS)
- By Short Acting Beta Agonists (SABA)
- By Long Acting Beta Agonists (LABA)
- By Leukotriene Antagonists (LTA)
- By Anticholinergics
- By Anti-Inflammatories
- By Other Classes
- South Korea Asthma and COPD Drugs Market, By Distribution Channel
- By Retail Pharmacies
- By Hospital Pharmacies
- By Online Pharmacies
- By Drug Stores
- South Korea Asthma and COPD Drugs Market, By Diseases
- South East Asia
- South East Asia Asthma and COPD Drugs Market, By Diseases
- By Asthma
- By COPD
- South East Asia Asthma and COPD Drugs Market, By Medication Class
- By Combination Drugs
- By Bronchodilators
- By Inhaled Corticosteroids (ICS)
- By Short Acting Beta Agonists (SABA)
- By Long Acting Beta Agonists (LABA)
- By Leukotriene Antagonists (LTA)
- By Anticholinergics
- By Anti-Inflammatories
- By Other Classes
- South East Asia Asthma and COPD Drugs Market, By Distribution Channel
- By Retail Pharmacies
- By Hospital Pharmacies
- By Online Pharmacies
- By Drug Stores
- South East Asia Asthma and COPD Drugs Market, By Diseases
- Rest of Asia Pacific
- Rest of Asia Pacific Asthma and COPD Drugs Market, By Diseases
- By Asthma
- By COPD
- Rest of Asia Pacific Asthma and COPD Drugs Market, By Medication Class
- By Combination Drugs
- By Bronchodilators
- By Inhaled Corticosteroids (ICS)
- By Short Acting Beta Agonists (SABA)
- By Long Acting Beta Agonists (LABA)
- By Leukotriene Antagonists (LTA)
- By Anticholinergics
- By Anti-Inflammatories
- By Other Classes
- Rest of Asia Pacific Asthma and COPD Drugs Market, By Distribution Channel
- By Retail Pharmacies
- By Hospital Pharmacies
- By Online Pharmacies
- By Drug Stores
- Rest of Asia Pacific Asthma and COPD Drugs Market, By Diseases
- China
-
Latin America Asthma and COPD Drugs Market - Segment Analysis
- Overview
- Latin America Asthma and COPD Drugs Market, 2016 - 2028 (USD Million)
-
Latin America Asthma and COPD Drugs Market, by Diseases
- By Asthma
- By COPD
-
Latin America Asthma and COPD Drugs Market, by Medication Class
- By Combination Drugs
- By Bronchodilators
- By Inhaled Corticosteroids (ICS)
- By Short Acting Beta Agonists (SABA)
- By Long Acting Beta Agonists (LABA)
- By Leukotriene Antagonists (LTA)
- By Anticholinergics
- By Anti-Inflammatories
- By Other Classes
-
Latin America Asthma and COPD Drugs Market, by Distribution Channel
- By Retail Pharmacies
- By Hospital Pharmacies
- By Online Pharmacies
- By Drug Stores
-
Latin America Asthma and COPD Drugs Market, by Country
- Brazil
- Brazil Asthma and COPD Drugs Market, By Diseases
- By Asthma
- By COPD
- Brazil Asthma and COPD Drugs Market, By Medication Class
- By Combination Drugs
- By Bronchodilators
- By Inhaled Corticosteroids (ICS)
- By Short Acting Beta Agonists (SABA)
- By Long Acting Beta Agonists (LABA)
- By Leukotriene Antagonists (LTA)
- By Anticholinergics
- By Anti-Inflammatories
- By Other Classes
- Brazil Asthma and COPD Drugs Market, By Distribution Channel
- By Retail Pharmacies
- By Hospital Pharmacies
- By Online Pharmacies
- By Drug Stores
- Brazil Asthma and COPD Drugs Market, By Diseases
- Argentina
- Argentina Asthma and COPD Drugs Market, By Diseases
- By Asthma
- By COPD
- Argentina Asthma and COPD Drugs Market, By Medication Class
- By Combination Drugs
- By Bronchodilators
- By Inhaled Corticosteroids (ICS)
- By Short Acting Beta Agonists (SABA)
- By Long Acting Beta Agonists (LABA)
- By Leukotriene Antagonists (LTA)
- By Anticholinergics
- By Anti-Inflammatories
- By Other Classes
- Argentina Asthma and COPD Drugs Market, By Distribution Channel
- By Retail Pharmacies
- By Hospital Pharmacies
- By Online Pharmacies
- By Drug Stores
- Argentina Asthma and COPD Drugs Market, By Diseases
- Rest of Latin America
- Rest of Latin America Asthma and COPD Drugs Market, By Diseases
- By Asthma
- By COPD
- Rest of Latin America Asthma and COPD Drugs Market, By Medication Class
- By Combination Drugs
- By Bronchodilators
- By Inhaled Corticosteroids (ICS)
- By Short Acting Beta Agonists (SABA)
- By Long Acting Beta Agonists (LABA)
- By Leukotriene Antagonists (LTA)
- By Anticholinergics
- By Anti-Inflammatories
- By Other Classes
- Rest of Latin America Asthma and COPD Drugs Market, By Distribution Channel
- By Retail Pharmacies
- By Hospital Pharmacies
- By Online Pharmacies
- By Drug Stores
- Rest of Latin America Asthma and COPD Drugs Market, By Diseases
- Brazil
-
Middle East & Africa Asthma and COPD Drugs Market - Segment Analysis
- Overview
- Middle East & Africa Asthma and COPD Drugs Market, 2016 - 2028 (USD Million)
-
Middle East & Africa Asthma and COPD Drugs Market, by Diseases
- By Asthma
- By COPD
-
Middle East & Africa Asthma and COPD Drugs Market, by Medication Class
- By Combination Drugs
- By Bronchodilators
- By Inhaled Corticosteroids (ICS)
- By Short Acting Beta Agonists (SABA)
- By Long Acting Beta Agonists (LABA)
- By Leukotriene Antagonists (LTA)
- By Anticholinergics
- By Anti-Inflammatories
- By Other Classes
-
Middle East & Africa Asthma and COPD Drugs Market, by Distribution Channel
- By Retail Pharmacies
- By Hospital Pharmacies
- By Online Pharmacies
- By Drug Stores
-
Middle East & Africa Asthma and COPD Drugs Market, by Country
- GCC Countries
- GCC Countries Asthma and COPD Drugs Market, By Diseases
- By Asthma
- By COPD
- GCC Countries Asthma and COPD Drugs Market, By Medication Class
- By Combination Drugs
- By Bronchodilators
- By Inhaled Corticosteroids (ICS)
- By Short Acting Beta Agonists (SABA)
- By Long Acting Beta Agonists (LABA)
- By Leukotriene Antagonists (LTA)
- By Anticholinergics
- By Anti-Inflammatories
- By Other Classes
- GCC Countries Asthma and COPD Drugs Market, By Distribution Channel
- By Retail Pharmacies
- By Hospital Pharmacies
- By Online Pharmacies
- By Drug Stores
- GCC Countries Asthma and COPD Drugs Market, By Diseases
- South Africa
- South Africa Asthma and COPD Drugs Market, By Diseases
- By Asthma
- By COPD
- South Africa Asthma and COPD Drugs Market, By Medication Class
- By Combination Drugs
- By Bronchodilators
- By Inhaled Corticosteroids (ICS)
- By Short Acting Beta Agonists (SABA)
- By Long Acting Beta Agonists (LABA)
- By Leukotriene Antagonists (LTA)
- By Anticholinergics
- By Anti-Inflammatories
- By Other Classes
- South Africa Asthma and COPD Drugs Market, By Distribution Channel
- By Retail Pharmacies
- By Hospital Pharmacies
- By Online Pharmacies
- By Drug Stores
- South Africa Asthma and COPD Drugs Market, By Diseases
- Rest of Middle East & Africa
- Rest of Middle East & Africa Asthma and COPD Drugs Market, By Diseases
- By Asthma
- By COPD
- Rest of Middle East & Africa Asthma and COPD Drugs Market, By Medication Class
- By Combination Drugs
- By Bronchodilators
- By Inhaled Corticosteroids (ICS)
- By Short Acting Beta Agonists (SABA)
- By Long Acting Beta Agonists (LABA)
- By Leukotriene Antagonists (LTA)
- By Anticholinergics
- By Anti-Inflammatories
- By Other Classes
- Rest of Middle East & Africa Asthma and COPD Drugs Market, By Distribution Channel
- By Retail Pharmacies
- By Hospital Pharmacies
- By Online Pharmacies
- By Drug Stores
- Rest of Middle East & Africa Asthma and COPD Drugs Market, By Diseases
- GCC Countries
-
Key Market Dynamics
- Introduction
- Market Drivers
- Market Restraints
- Market Opportunities
- Porter's Five Forces Analysis
- PEST Analysis
- Regulatory Landscape
- Technology Landscape
- Regional Market Trends
-
COVID 19 Impact Analysis
- Key strategies undertaken by companies to tackle COVID-19
- Short term dynamics
- Long term dynamics
-
Marketing Stratagy Analysis
- Marketing Channel
- Direct Marketing
- Indirect Marketing
- Marketing Channel Development Trends
-
Competative Landscape
- Competition Matrix - 2021
- Company Market Share Analysis - 2021
- Key Company Activities, 2018 - 2021
- Strategic Developments - Heat Map Analysis
- Company Offering Evaluation
- Company Regional Presence Evaluation
-
Company Profiles
- Novartis AG (Switzerland)
- Cipla Inc. (India)
- Abbott Laboratories (U.S.)
- Astellas Pharma (Japan)
- Hoffmann-La Roche Ltd. (Switzerland)
- Glenmark Pharmaceuticals (India)
- Verona Pharma PLC (UK)
- AstraZeneca (UK)
- GSK (UK)
- Pfizer Inc. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Merck & Co. Inc. (U.S.)
- Grifols S.A. (Spain)
- Key Primary Respondents - VERBATIM
- Discussion Guide
- Customization Offered
- Annexure
- List of Figures
- List of Tables
- List of Abbreviations
FAQ
Frequently Asked Question
What is the global demand for Asthma and COPD Drugs in terms of revenue?
-
The global Asthma and COPD Drugs valued at USD 37.42 Billion in 2023 and is expected to reach USD 57.56 Billion in 2032 growing at a CAGR of 4.9%.
Which are the prominent players in the market?
-
The prominent players in the market are Novartis AG (Switzerland), Cipla Inc. (India), Abbott Laboratories (U.S.), Astellas Pharma (Japan), Hoffmann-La Roche Ltd. (Switzerland), Glenmark Pharmaceuticals (India), Verona Pharma PLC (UK), AstraZeneca (UK), GSK (UK), Pfizer Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Merck & Co. Inc. (U.S.), Grifols S.A. (Spain).
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 4.9% between 2024 and 2032.
What are the driving factors fueling the growth of the market.
-
The driving factors of the Asthma and COPD Drugs include
- The rising incidence of asthma and COPD globally is a significant driver for the market, primarily fueled by several interconnected factors
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the Asthma and COPD Drugs in 2023.